Noemie Luong
Associate Principal Scientist, Translational Pharmacology Debiopharm
Noémie Luong is Associate Principal Scientist in Translational Pharmacology at Debiopharm, where she plays a key role in advancing oncology drug development programs, particularly in the DNA damage response (DDR) and ADC fields. In this role, she contributes to the translation of preclinical discoveries into clinical strategies, supporting the development of targeted therapies aimed at improving outcomes for patients with difficult-to-treat cancers.
Luong has built her career at Debiopharm across research, evaluation, and translational science roles, bringing deep expertise in pharmacology, biomarker-driven development, and precision oncology. She holds a Ph.D. in Immunology and Cancer Research from the University of Lausanne and is passionate about developing innovative therapies that address unmet medical needs in oncology.
Seminars
- Explaining the impact of ADC innovation to improve and widen therapeutic index and potentially maximize patient benefit
- Laying out MultiLINK novel linker-payload preclinical performance and mechanistic characterization to understand effect on tumor cells
- Contextualizing novel linker-payload preclinical proof-of-concept to enhance ADC tolerability and therapeutic index
- Maximizing therapeutic impact against low expressing targets and rapidly proliferating tumors using targeted high DAR ADC architectures
- Addressing current ADC challenges with novel linker-payloads: Preclinical proof-of-concept to preserve efficacy while enhancing ADC tolerability and therapeutic index
- Detailing novel linker mechanism for safer sequential release of MMAE
